Novel ADC Conjugates

Summary: Antibody-drug conjugates (ADCs) are a novel class of drugs that combine the potency of small molecule drugs with the targeting capabilities of highly-specific antibodies. While there is a wide array of different biochemical methods used for making ADCs, each method can have a varying effect on the stability of these types of therapeutics. In addition, the production of antibodies can be inherently complex and heterogeneous. Together, these challenges present a significant barrier to companies engaging in ADC drug development.

A novel ADC case study will be presented to highlight development success.

Topics covered in this webinar:

• ADC analytical characterization techniques and current regulatory expectations
• Alternative approaches to quantitate ADC DAR.
• Optimizing bench-scale conjugation.

Presenter:

Benjamin Buer, Ph.D.
Associate Director, Pharmaceutical Development
Pace Analytical Life Sciences